Joan D Beckman
LightNews LightNews
banner
jdbeckman.bsky.social
Joan D Beckman
@jdbeckman.bsky.social
490 followers 580 following 62 posts
Lois & Richard King Assistant Professor of Medicine at University of Minnesota- hematology physician scientist, mother, cat lady, & ND native. Excited for Gopher and Bison sports, sickle cell and MPN vascular biology, and rare bleeding disorders.
Posts Replies Media Videos
jdbeckman.bsky.social
Our snowblower is in the shop so we did our driveway by hand. My watch recorded 55 min of activity and I walked 1.8 miles. I was sweating through my layers. #mn winter is here!
November 30, 2025 at 4:46 PM
Reposted by Joan D Beckman
shematologist.medsky.social
Every dollar counts when it comes to feeding people!

Even $5 can go along way especially with organizations @feedthechildrenorg.bsky.social having 8x matching.

We can all make a difference.
shematologist.medsky.social Shematologist, MD @shematologist.medsky.social · 22h
In 48 hours we’ve raised over $100k to feed those in need through #HCWvsHunger, an annual competition to raise money for the food banks YOU CHOOSE.

Donate today and log your donation for your favorite team at HCWvsHunger.org

And if you can’t donate, please repost!
Healthcare Workers vs Hunger
Healthcare workers vs Hunger is an annual friendly competition between teams of healthcare workers to help relieve food insecurity.
HCWvsHunger.org
November 29, 2025 at 11:57 PM
jdbeckman.bsky.social
hcwvshunger.org
Healthcare Workers vs Hunger
Healthcare workers vs Hunger is an annual friendly competition between teams of healthcare workers to help relieve food insecurity.
hcwvshunger.org
November 30, 2025 at 12:42 AM
Reposted by Joan D Beckman
hemehub.bsky.social
Further results from the Exa-cel study.

Focus: CLIMB SCD-121 Trial

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy #HematopoieticStemCells
October 22, 2025 at 10:58 PM
Reposted by Joan D Beckman
hemehub.bsky.social
Our session with Dr. Thomas Coates is in 2 weeks!

Don’t miss this opportunity to hear from a top expert in the field!

🔗Register now:
hemehub.org/live-events

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine
hemehub.bsky.social hemehub.bsky.social @hemehub.bsky.social · Oct 18
🩸Join us for an exclusive webinar with Dr. Thomas Coates, focusing on advances in the management of sickle cell disease, vascular complications, and transfusion-related iron overload.

Register now: hemehub.org/live-events

#Hematology #SickleCellDisease #BloodDisorders #MedicalEducation
October 22, 2025 at 10:58 PM
jdbeckman.bsky.social
www.linkedin.com/posts/htrsto...
@htrstoday.bsky.social thank you for supporting this program and the three Beckman Lab students attending!
HTRS is excited to welcome the accepted students for our third SEARCH Workshop happening in just 10 days! We can’t wait to connect, learn, and advance the future of hemostasis and thrombosis… | Hemo...
HTRS is excited to welcome the accepted students for our third SEARCH Workshop happening in just 10 days! We can’t wait to connect, learn, and advance the future of hemostasis and thrombosis researc...
www.linkedin.com
October 11, 2025 at 2:47 PM
jdbeckman.bsky.social
Another #caturday where Oscar has decided he is better at reviewing papers than I am. Big Boy is just annoyed.
September 27, 2025 at 5:19 PM
jdbeckman.bsky.social
Two of my favorite mentors- Dr Vercellotti and Dr Key at Blood Club at UMN
September 25, 2025 at 11:55 PM
jdbeckman.bsky.social
#caturday
September 13, 2025 at 6:08 PM
jdbeckman.bsky.social
My scheduled appointment @memorialblood.bsky.social was late today because of so many walk ins. Minnesotans help each other! Happy to wait and to do my small part to help the injured.
August 27, 2025 at 10:26 PM
Reposted by Joan D Beckman
bloodjournals.hematology.org
JAK2V617F neutrophils evade homeostatic clearance and accumulate in MPN owing to JAK2-STAT5–dependent upregulation of CD24. buff.ly/eujxmx2 #hemesky
August 13, 2025 at 7:01 PM
jdbeckman.bsky.social
Excited to do this research!
August 2, 2025 at 8:13 PM
jdbeckman.bsky.social
Did my best to get everyone but alas- missing a few! Beckman lab (minus 4!) summer 2025
July 30, 2025 at 11:54 PM
jdbeckman.bsky.social
The airplane ears are because he really really liked this proposal- to sit on:) trying not to let my #caturday grant review helper influence my scores too much. Nice to have the company.
July 12, 2025 at 7:20 PM
Reposted by Joan D Beckman
georgetakei.bsky.social
Recently, my book THEY CALLED US ENEMY was banned – again – in Tennessee. Book bans are out of control. Huge parts of American history are being restricted. To join me in standing up for the freedom to read, go to pen.org/action. @penamerica.bsky.social @topshelfcomix.bsky.social @idwpublishing.com
July 11, 2025 at 9:05 PM
Reposted by Joan D Beckman
mdaware.org
"It feels like they're using DEl as a euphemism for another word, another derogatory word towards people that they don't like," he said.
July 4, 2025 at 2:32 PM
jdbeckman.bsky.social
Just saw the biosafety cabinet I did my PhD in being carted away down the street- it died and a replacement in en route—- odd returning back to the old lab to start my own- grateful that my “previously used” stuff is holding up
July 1, 2025 at 1:24 PM
jdbeckman.bsky.social
Congrats to Maya for her poster @isth.org
June 22, 2025 at 8:38 PM
jdbeckman.bsky.social
Nigel Key lab alumni @isth.org #ISTH2025 @unc-brc.bsky.social
June 22, 2025 at 8:37 PM
Reposted by Joan D Beckman
kumail.bsky.social
A Dem lawmaker and her husband were killed by a guy for their political views and it’s already out of the news.
June 21, 2025 at 11:05 PM
Reposted by Joan D Beckman
voxeu.org
Data from over 80,000 US school principals shows that when a school needs to contact a parent, the mother is 1.4 times more likely than the father to receive the first call.
@kbuzard7.bsky.social‬ @laurakgee.bsky.social @olgastoddard.bsky.social
cepr.org/voxeu/column...
#EconSky
Chart showing how mothers are more likely to receive the first contact from schools than fathers. Mothers continue to shoulder the majority of childcare responsibilities even in dual-earner households, contributing to gender gaps in earnings, labour force participation, and career advancement. This column uses an experiment targeting over 80,000 US school principals to show that when a school needs to contact a parent, the mother is 1.4 times more likely than the father to receive the first call. A further survey saw mothers consistently identified as the primary point of contact across a wide range of domains, including doctors, sports coaches, and religious leaders. Suggestive evidence points to gendered interruptions contributing to broader economic inequality.
June 17, 2025 at 8:15 AM
Reposted by Joan D Beckman
amarshallmd.bsky.social
#LEAD2025 is here! #Leadership for women in #Hematology and #Oncology
1. Clinical updates
2. #CareerDevelopment (Im talking on #burnout and #wellbeing)
3. #Networking
REGISTER HERE: bioascend.com/lead/
#Empowerment #WomenInMedicine #MedSky #MedEd
June 10, 2025 at 12:15 AM
Reposted by Joan D Beckman
sicklecelluk.bsky.social
Live with Sickle Cell Disease? Aged 18+ & registered with a haematology team in England?

Join the RISE Study! 💬 Help shape better self-management tools through online group sessions.

🔗 buff.ly/lRBoomL
📧 [email protected]
#SickleCell #RISEStudy
June 6, 2025 at 8:01 AM
jdbeckman.bsky.social
So a senior male scientist interrupted me during a lab meeting presentation to randomly ask if anyone wanted the possum he caught as a pet 😳🤷🏻‍♀️ — and that has been the highlight of all the chaos.
a blue dumpster is floating in a flooded area near a sign that says narrows ramp
ALT: a blue dumpster is floating in a flooded area near a sign that says narrows ramp
media.tenor.com
June 5, 2025 at 9:32 AM
jdbeckman.bsky.social
dailynews.ascopubs.org/do/ropeginte...
Ropeginterferon Alfa-2b Demonstrates Superior Efficacy and Safety to Anagrelide as Second-Line Therapy for Essential Thrombocythemia
The phase 3 SURPASS-ET trial results show superior efficacy and safety of ropeginterferon alfa-2b compared with anagrelide as second-line therapy for essential thrombocythemia (Abstract 6500).
dailynews.ascopubs.org
June 4, 2025 at 10:38 AM